CHU JENNIFER HSING-CHUNG,SHAH GAUTAM,PHADKE AVINASH
申请号：
IN8160/DELNP/2015
公开号：
IN2015DN08160A
申请日:
2015.09.09
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC) HPC (hydroxypropyl cellulose) hypromellose acetate succinate (HPMCAS) polyvinyl pyrrolidone (PVP) copovidone (PVP VA) a copolymer of methacrylic acid and ethyl acrylate or any combination of the foregoing wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.
